Physician profile
Ayman Gebrail
NPI 1033105507
$17,324.76
in general payments reported to CMS, 2019-2025
70 companies · $2,486 in 2025
The $2,486 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,559 · 2020: $1,645 · 2021: $2,211 · 2022: $2,143 · 2023: $2,484 · 2024: $2,797 · 2025: $2,486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,766.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,853.13 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $2,181.38 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,746.86 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $943.30 | 2019-2025 | |
| Pfizer INC. | $878.38 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $664.07 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $636.04 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $544.49 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amgen INC. | $544.42 | 2019-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $488.40 | 2019-2024 | Xarelto, Spravato |
| Axsome Therapeutics, INC. | $412.23 | 2023-2025 | Auvelity, Sunosi, Symbravo |
| Abbott Laboratories | $410.48 | 2021-2025 | Freestyle Libre 3, Eterna, Freestyle Libre |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $388.51 | 2019-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $358.30 | 2019-2025 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $312.39 | 2019-2024 | Trintellix |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayman Gebrail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.